With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.
Thinking about how IP can assist a company long before it has fully developed is essential, says Leda Trivinos of Flagship Pioneering in an interview with LSIPR.
Anthony Atala combines the roles of surgeon and researcher in regenerative medicine, allowing him to stay mindful of why his work is important. He talks to LSIPR about his twin professions.
Mike Young was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
Now that Costa Rica has allowed adult stem cells to be used as part of regenerative therapies, the country should be able to attract more investment, say María del Pilar López and Esteban Monge of Zürcher Lawyers.
A handful of high-profile disputes over medical use patents have been decided in Japan, as Osamu Yamamoto of Yuasa and Hara reports.
India’s regulatory environment surrounding pharmaceuticals and medical devices needs to evolve in order to unlock the industries’ true potential, says Kirit Javali of Jafa & Javali.
A new EU regulation on implantable medical devices takes steps to acknowledge that patient outcomes and safety are primary goals, but the transition to the new system might not be easy for industry stakeholders, says Jo Emmett of Premier Research.
As securing patent eligibility for ‘healthcare IT’ applications seems to be becoming easier, companies looking to monetise IP in this area can breathe a sigh of relief. Stacy Taylor of DLA Piper explains more.
IP law has yet to catch up with the technological capabilities of 3D printing, but by taking pre-emptive action, companies can maximise their IP protection under the current legal framework. Arlene Chow and Nitya Anand of Hogan Lovells report.